Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00146211 · ClinicalTrials.gov registry record · Phase 3

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

A Phase 3 study of Huntington Disease, sponsored by Amarin Neuroscience.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target
20
Study locations

NCT00146211 is a Phase 3 study of Huntington Disease that has completed, run by Amarin Neuroscience. The registered enrollment target is 300 participants, below the 627-participant average among 35 other Huntington Disease trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00146211, a Phase 3 study of Huntington Disease, has completed, sponsored by Amarin Neuroscience.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.

Conditions Studied

Huntington Disease

Interventions

  • DRUG Ethyl-EPA (Miraxion™)

Study Locations (20)

California

  • University of California San Diego - La Jolla
  • UCLA Medical Center - Los Angeles
  • University of California Davis - Sacramento
  • University of California San Francisco - San Francisco

Florida

  • University of Florida - Gainesville
  • University of Miami - Miami
  • University of South Florida - Tampa

Georgia

  • Emory University - Atlanta
  • Medical College of Georgia - Augusta

Illinois

  • Rush University Medical Center - Chicago
  • University of Chicago - Chicago

Kansas

  • University of Kansas - Kansas City
  • Hereditary Neurological Disease Centre - Wichita

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic Arizona - Scottsdale

Colorado

  • Colorado Neurological Institute - Englewood

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2005-09
Est. Completion 2007-07
Phase Phase 3

Sponsor

Amarin Neuroscience

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00146211

The ClinicalTrials.gov registry entry for NCT00146211 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 627-participant average among 35 other Huntington Disease trials with a reported enrollment target (52% lower). The listed sponsor is Amarin Neuroscience, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Ethyl-EPA (Miraxion™) is the first listed.

NCT00146211 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00146211 about?

NCT00146211 is a clinical study titled "TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease". This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.

What is the current status of trial NCT00146211?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2005-09. Estimated completion is 2007-07.

What conditions does trial NCT00146211 study?

This clinical trial studies the following conditions: Huntington Disease.

What interventions are being tested in trial NCT00146211?

The interventions under investigation include: Ethyl-EPA (Miraxion™) (DRUG).

Who is sponsoring clinical trial NCT00146211?

This trial is sponsored by Amarin Neuroscience, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00146211 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Huntington Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Huntington Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.